Are Wall Street Analysts Bullish on Cigna Group Stock?

Headquartered in Bloomfield, Connecticut, The Cigna Group (CI) is a global health company focused on improving health and vitality. Through Cigna Healthcare and Evernorth Health Services, it provides healthcare and related services to more than 185 million customer relationships across over 30 markets and jurisdictions. It has a market capitalization of $74.6 billion.

Shares of this leading healthcare company have underperformed the broader market over the past year. CI has gained 1.3% over this period, while the broader S&P 500 Index ($SPX) has climbed nearly 21.3%. The stock has also considerably underperformed the index in 2026, gaining 1.2% year-to-date, compared with the S&P 500’s 13.3% gain over the same period.

Compared with the iShares U.S. Healthcare Providers ETF (IHF), CI has also underperformed, as the ETF has climbed 34.4% over the past year and 19.5% on a YTD basis.

On July 30, The Cigna Group reported its Q2 FY2026 earnings, with shares falling 3% despite results topping expectations. Adjusted revenues grew 6.6% to $71.7 billion, driven by growth in both Evernorth Health Services and Cigna Healthcare. Adjusted income from operations rose 8.1% to $7.78 per share. Cigna raised its full-year 2026 outlook for adjusted income from operations to at least $30.45 per share, up $0.10 from its prior projection. The company also raised its outlook for Cigna Healthcare’s adjusted income from operations, pre-tax, to at least $4.55 billion, up $25 million, while maintaining Evernorth’s outlook of at least $6.9 billion.

Analysts expect CI’s diluted EPS to rise 2.3% year over year to $30.51 for the fiscal year ending in December 2026. CI has surpassed consensus EPS estimates in each of the past four quarters, reflecting consistent earnings performance.

Based on the 23 analysts covering CI stock, the consensus rating is a “Moderate Buy.” The rating is based on 14 “Strong Buy” ratings, three “Moderate Sell” ratings, and six “Hold” ratings.

This configuration is more bearish than it was a month ago, when the stock had 16 “Strong Buy” ratings.

On August 3, Goldman Sachs raised its price target for Cigna Group to $352 from $340 while maintaining a “Buy” rating. 

Based on analysts’ estimates, the mean price target of $341.61 implies a 22.7% premium to CI’s current share price, while the Street-high price target of $400 suggests a 43.7% upside.